SCHEMBL1432945

SCHEMBL1432945

CCOC(=O)c1ncnn1Cc1c(-c2ccc(Cl)cc2)nc2ccc(Cl)cn12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC2A1 P11166 2/20 0.56
▸ CYP1A2 P05177 1/20 0.54
▸ CYP2C9 P11712 1/20 0.54
▸ CYP2C19 P33261 1/20 0.54
▸ TSPO P30536 3/20 0.52
▸ NR1I2 O75469 1/20 0.52
▸ ABCB11 O95342 1/20 0.52
▸ ALB P02768 1/20 0.52
▸ ADORA3 P0DMS8 1/20 0.52
▸ ADORA1 P30542 1/20 0.52
▸ OPRM1 P35372 1/20 0.52
▸ DRD3 P35462 1/20 0.52
▸ OPRK1 P41145 1/20 0.52
▸ PDE4D Q08499 1/20 0.52
▸ KCNH2 Q12809 1/20 0.52
▸ SLC2A2 P11168 1/20 0.52
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ GABRA2 P47869 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2225808 0.90 SLC2A1 (0.49) SLC2A1TSPONR1I2ABCB11ALB
SCHEMBL2178544 0.88 ALDH1A1 (0.49) SLC2A1TSPONR1I2ABCB11ALB
SCHEMBL4324580 0.86 SLC2A1 (0.53) SLC2A1TSPONR1I2ABCB11ALB
SCHEMBL2197080 0.85 SLC2A1 (0.52) SLC2A1TSPONR1I2ABCB11ALB
SCHEMBL2179254 0.85 CYP1A2 (0.52) SLC2A1CYP1A2CYP2C9CYP2C19SLC2A2
SCHEMBL2196283 0.84 ALDH1A1 (0.55) SLC2A1TSPONR1I2ABCB11ALB
SCHEMBL2180865 0.84 SLC2A1 (0.49) SLC2A1TSPONR1I2ABCB11ALB
SCHEMBL1429966 0.84 ALDH1A1 (0.52) SLC2A1TSPONR1I2ABCB11ALB
SCHEMBL1430522 0.83 SLC2A1 (0.56) SLC2A1CYP1A2CYP2C9CYP2C19TSPO
SCHEMBL2178982 0.82 TSPO (0.46) SLC2A1TSPONR1I2ABCB11ALB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. 2013-10-31 — — US disclosed
US-8497278-B2 Imidazo[1,2-a]pyridine compounds SUNOVION PHARMACEUTICALS INC. (US) 2013-07-30 — — US disclosed
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. (US) 2011-07-07 — — US disclosed
EP-2300470-A2 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS GABA-A RECEPTOR MODULATORS Sepracor Inc. (US) 2011-03-30 — — EP disclosed
WO-2009143156-A2 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SEPRACOR INC. (US) 2009-11-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD SLC2A1 2033/4885CYP1A2 61/4885CYP2C9 185/4885
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD SLC2A1 2033/4885CYP1A2 61/4885CYP2C9 185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback